Unity Biotechnology (NASDAQ:UBX) vs. Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Analysis

Unity Biotechnology (NASDAQ:UBX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Unity Biotechnology and Carisma Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0	0	3	0	3.00
Carisma Therapeutics	0	0	2	1	3.33

Unity Biotechnology presently has a consensus target price of $6.67, suggesting a potential upside of 429.10%. Carisma Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 645.55%. Given Carisma Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and Carisma Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Carisma Therapeutics	-314.78%	-957.20%	-96.39%

Institutional and Insider Ownership

29.5% of Unity Biotechnology shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 5.8% of Unity Biotechnology shares are owned by insiders. Comparatively, 12.6% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Unity Biotechnology has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Earnings & Valuation

This table compares Unity Biotechnology and Carisma Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240,000.00	88.46	-$39.86 million	($1.31)	-0.96
Carisma Therapeutics	$14.92 million	2.63	-$86.88 million	($1.56)	-0.60

Unity Biotechnology has higher earnings, but lower revenue than Carisma Therapeutics. Unity Biotechnology is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Carisma Therapeutics beats Unity Biotechnology on 8 of the 15 factors compared between the two stocks.

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.